RUA Life Sciences Doubles Revenue and Turns EBITDA Positive in Final Results

RUA Life Sciences final results: revenue doubled and EBITDA turns positive

RUA Life Sciences has delivered a strong set of final results for the 18 months to 30 September 2025 after shifting the business decisively toward commercial growth. Revenue more than trebled to £6.689 million, EBITDA moved into the black at £0.4 million, and the pre-tax loss narrowed sharply to £0.236 million.

This period is 18 months (due to a year-end change), so not directly comparable to the 12 months to March 2024. Even so, like-for-like growth was punchy at 104%, and the company is now clearly oriented around delivering for customers as a CDMO – that’s a contract development and manufacturing organisation – while monetising its polymer IP.

Key numbers investors should know

Metric	18 months to 30 Sep 2025	12 months to 31 Mar 2024
Revenue	£6.689 million	£2.191 million
Like-for-like revenue growth	104%	Not applicable
CDMO (Medical Devices & Components) revenue	£5.775 million	£1.695 million
Biomaterials (Elast-Eon licensing) revenue	£914,000	£496,000
EBITDA	£0.4 million	£1.6 million loss
Loss before tax	£0.236 million	£2.020 million
Underlying loss before tax (excl. bargain purchase)	£1.1 million	Not disclosed
Non-cash gain on bargain purchase (Abiss)	£0.895 million	£0
Cash at period end	£3.250 million	£3.931 million
Basic loss per share	0.35 pence	4.29 pence
Operating cash outflow from operations	£0.193 million	£1.328 million

What drove the improvement: CDMO growth and the Abiss acquisition

The standout driver is the Medical Devices and Components division. UK operations delivered £3.6 million (53% of Group revenue) with 41% like-for-like growth as RUA picked up new business and ramped volumes for existing customers. The September 2024 acquisition of Abiss added a continental European platform and £2.2 million (33% of Group revenue), broadening both capability and customer reach.

Abiss also produced a non-recurring accounting gain of £0.9 million on “bargain purchase”. That reflects buying a distressed asset for less than the fair value of its net assets. It flatters the bottom line this period, but the operational logic is the real win: the deal secures supply to a major customer and embeds RUA deeper in the medical device value chain.

For completeness, Abiss contributed a £0.2 million loss before tax from acquisition to period end, and the company flags a reliance on a single major customer in that business. That is a watchpoint, but it comes with the opportunity to cross-sell and diversify from a stronger base.

Biomaterials and Elast-Eon: resilient licensing despite FX headwinds

Biomaterials delivered £914,000 of revenue (14% of Group), up from £496,000 last year, with like-for-like growth of 23% despite periods of Sterling strength against the US dollar. This is licensing income from Elast-Eon, a long-term implantable polyurethane. The pipeline here includes devices at design, development and regulatory stages, which can build future royalties if they progress.

Geographically, sales are predominantly into North America (£5.396 million), with Europe at £1.173 million. That concentration isn’t unusual in medtech, but it’s useful context for currency and regulatory exposure.

Profitability, cash, and operating discipline

EBITDA turned positive at £0.4 million, a £2.0 million swing driven by higher revenues and better gross margins, plus the Abiss gain. The loss before tax reduced to £0.236 million. If you strip out the £0.895 million bargain purchase gain, the underlying loss before tax was £1.1 million – still a material improvement.

Cash performance was notably tighter. Operating cash outflow from operations was just £0.193 million for the 18 months, and the final six months generated a net cash inflow from operating activities. Period-end cash was £3.250 million after repaying a £0.11 million mortgage. As at approval of the accounts, cash was approximately £2.8 million, and the Board has prepared forecasts supporting going concern for at least 12 months.

Costs were kept on a leash. General and administrative expenses were £6.5 million for the extended period, and R&D spend was cut to £0.4 million from £0.9 million as the company prioritised customer delivery and near-term profitability. Management intends to reduce R&D further unless third-party funded.

IP portfolio: optionality with a commercial lens

There is a meaningful bank of internal IP:

• Elast-Eon for long-term implants and AurTex composite processing technology.
• Heart valve materials work (AurTex and Elast-Eon leaflet technology) under selective continued development, with the Board aiming to move future activity “off book”.
• Vascular graft technology – no further investment currently, but elements are already generating early-stage component revenues.
• Pelvic floor and SUI (stress urinary incontinence) devices and next-generation materials.

The strategy is pragmatic: partner where others carry the regulatory and clinical burden, with RUA providing contract development and manufacturing, and monetising via royalties or similar. In other words, keep the capital-light upside while avoiding long, cash-absorbing product approvals on the balance sheet.

Why this matters for shareholders

• Evidence of execution: revenue doubled on a like-for-like basis and EBITDA turned positive. That’s the right trajectory for a former R&D-led group pivoting to commercial contracts.
• Stickier relationships: embedding at the design and development stage increases the probability of long-term manufacturing supply once products are approved. Lifecycles of 10-20 years create visibility when you win.
• Diversified model: CDMO growth plus recurring licensing income gives a more balanced mix – 86% devices/components, 14% biomaterials this period.
• Cash discipline: operating cash burn reduced sharply, and period-end cash of £3.250 million provides runway while management pursues further growth.

Risks and watchpoints to keep in mind

• Non-recurring uplift: the £0.895 million bargain purchase gain helped reported profits this period. Underlying profitability still needs to push through breakeven.
• Customer concentration at Abiss: the acquisition rationale is sound, but reliance on a major customer heightens execution risk until diversified.
• Long medtech cycles: regulatory timelines are measured in years. RUA’s integrated CDMO positioning helps, but patience is a feature of the sector.
• FX exposure: Biomaterials royalties faced a Sterling headwind at points in the period; this can cut both ways in future.

Outlook: momentum maintained and pipelines building

Management says activity levels have continued into the current year with encouraging new business pipelines. Priorities are clear: grow Biomaterials licence income, scale contract manufacturing further (both UK and EU via Abiss), and actively monetise the broader IP portfolio.

My take: these results mark a credible step toward sustainable profitability. The mix is improving, cash is being managed tightly, and the business now has tangible operating leverage as new programmes move from development into volume supply. The key tells over the next 12 months will be sustained operating cash generation, new licensing wins, and customer diversification at Abiss. If RUA delivers those, today’s progress could compound nicely.